Irinotecan (Iri) in combination with high-dose infusional...

Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)

P. Rougier, D. Cunningham, A.D. Roth, J.R. Germa, R.D. James, P. Karasek, P. Jandik, T. Iveson, J. Carmichael, G. Gruia, M. Alakl, D. Sibaud, J.Y. Douillard
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
35
Year:
1999
Language:
english
DOI:
10.1016/s0959-8049(99)80639-x
File:
PDF, 117 KB
english, 1999
Conversion to is in progress
Conversion to is failed